HOWL werewolftx.com: Projected Price to Earnings

The recruitment of elite oncobiologists to develop PREDATOR cytokines is driving the publication of test results, which the daily forward P/E chart for Werewolf Therapeutics (HOWL) on GURU.Markets reflects through price action. The value of 0.00 represents the metric's baseline, while the overall financial stability of Werewolf Therapeutics relies exclusively on its ability to attract external capital to fund research.

Werewolf Therapeutics - HOWL Future Price to Earnings Multiple (period 07/04/2022 - 11/12/2026)

Metric breakdowns and analytics for Werewolf (HOWL)

- stock quotes and analyst forecast:

Stock Price Werewolf Therapeutics|HOWL - Analyst Target Range

- company stock capitalization data:

Market Valuation Werewolf Therapeutics Inc.|HOWL - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Werewolf Therapeutics|HOWL - Accounting Value of Company|Market Capitalization to Book Value Ratio werewolftx.com|HOWL - Company Total Asset Base

- debt level and financial liquidity data:

- financial results and valuation multiples details:

HOWL - Company Net Income|Future Profit Werewolf Therapeutics|HOWL - Market Cap to Net Income Ratio|Projected Price to Earnings Werewolf Therapeutics|HOWL - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Werewolf Therapeutics Inc.|HOWL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Werewolf Therapeutics|HOWL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months werewolftx.com|HOWL - Earnings per share increase in current year|Earnings growth forecast for next year Werewolf Therapeutics

Fundamental company analysis:Werewolf Therapeutics, Inc. HOWL

Signature product of Werewolf Therapeutics

The development of the PREDATOR platform in the field of targeted immuno-oncology drives the high valuation of Werewolf Therapeutics (HOWL) research and development assets. The forward P/E ratio compares the current market value of the business with projected annual net income, allowing for an assessment of the premium paid for innovation potential via the company's forward P/E chart to identify fair value points.

Analysis of competing companies